Skip to main content
NCBI home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1985 Sep 7;291(6496):623–627. doi: 10.1136/bmj.291.6496.623

Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide.

R H Mak, C Turner, T Thompson, H Powell, G B Haycock, C Chantler
PMCID: PMC1417527  PMID: 3928054

Abstract

Secondary hyperparathyroidism was suppressed over a period of one year in 12 children with chronic renal failure by using a regimen of mild dietary phosphate restriction and high dose phosphate binders. The patients were randomised to receive either aluminium hydroxide or calcium carbonate by mouth for six months and then crossed over to the other medication. Vitamin D (dihydrotachysterol) dosage was unchanged. Serum parathyroid hormone concentrations were reduced to within the normal range, urinary cyclic adenosine monophosphate values fell, plasma phosphate concentrations decreased, and the theoretical renal phosphate threshold increased significantly. Transiliac bone biopsy findings improved in four patients with adequate suppression of parathyroid hormone concentrations, deteriorated in two patients who were not compliant, and did not change in five patients in whom initial bone disease was mild. Growth velocity improved significantly. There was no difference in the clinical response, biochemical changes, or incidence of complications during treatment with the two agents. In view of the risk of aluminium toxicity the use of high dose calcium carbonate with dietary phosphate restriction and vitamin D supplementation is recommended in the control of secondary hyperparathyroidism in children with chronic renal failure.

Full text

PDF
623

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreoli S. P., Bergstein J. M., Sherrard D. J. Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis. N Engl J Med. 1984 Apr 26;310(17):1079–1084. doi: 10.1056/NEJM198404263101704. [DOI] [PubMed] [Google Scholar]
  2. Biswas C. K., Arze R. S., Ramos J. M., Ward M. K., Dewar J. H., Kerr D. N., Kenward D. H. Effect of aluminium hydroxide on serum ionised calcium, immunoreactive parathyroid hormone, and aluminium in chronic renal failure. Br Med J (Clin Res Ed) 1982 Mar 13;284(6318):776–778. doi: 10.1136/bmj.284.6318.776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bricker N. S. On the pathogenesis of the uremic state. An exposition of the "trade-off hypothesis". N Engl J Med. 1972 May 18;286(20):1093–1099. doi: 10.1056/NEJM197205182862009. [DOI] [PubMed] [Google Scholar]
  4. Brown E. M., Wilson R. E., Eastman R. C., Pallotta J., Marynick S. P. Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab. 1982 Jan;54(1):172–179. doi: 10.1210/jcem-54-1-172. [DOI] [PubMed] [Google Scholar]
  5. Broyer M., Kleinknecht C., Loirat C., Marti-Henneberg C., Roy M. P. Growth in children treated with long-term hemodialysis. J Pediatr. 1974 May;84(5):642–649. doi: 10.1016/s0022-3476(74)80003-x. [DOI] [PubMed] [Google Scholar]
  6. Chantler C., Barratt T. M. Estimation of glomerular filtration rate from plasma clearance of 51-chromium edetic acid. Arch Dis Child. 1972 Aug;47(254):613–617. doi: 10.1136/adc.47.254.613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Clarkson E. M., McDonald S. J., De Wardener H. E. The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure. Clin Sci. 1966 Jun;30(3):425–438. [PubMed] [Google Scholar]
  8. Counahan R., Chantler C., Ghazali S., Kirkwood B., Rose F., Barratt T. M. Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch Dis Child. 1976 Nov;51(11):875–878. doi: 10.1136/adc.51.11.875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Griswold W. R., Reznik V., Mendoza S. A., Trauner D., Alfrey A. C. Accumulation of aluminum in a nondialyzed uremic child receiving aluminum hydroxide. Pediatrics. 1983 Jan;71(1):56–58. [PubMed] [Google Scholar]
  10. Hodson E. M., Shaw P. F., Evans R. A., Dunstan C. R., Hills E. E., Wong S. Y., Rosenberg A. R., Roy L. P. Growth retardation and renal osteodystrophy in children with chronic renal failure. J Pediatr. 1983 Nov;103(5):735–740. doi: 10.1016/s0022-3476(83)80467-3. [DOI] [PubMed] [Google Scholar]
  11. Ibels L. S., Alfrey A. C., Haut L., Huffer W. E. Preservation of function in experimental renal disease by dietary restriction of phosphate. N Engl J Med. 1978 Jan 19;298(3):122–126. doi: 10.1056/NEJM197801192980302. [DOI] [PubMed] [Google Scholar]
  12. Kaplan M. A., Canterbury J. M., Bourgoignie J. J., Veliz G., Gavellas G., Reiss E., Bricker N. S. Reversal of hyperparathyroidism in response to dietary phosphorus restriction in the uremic dog. Kidney Int. 1979 Jan;15(1):43–48. doi: 10.1038/ki.1979.6. [DOI] [PubMed] [Google Scholar]
  13. Lawrence R. Assay of serum inorganic phosphate without deproteinisation: automated and manual micromethods. Ann Clin Biochem. 1974 Nov;11(6):234–237. doi: 10.1177/000456327401100168. [DOI] [PubMed] [Google Scholar]
  14. Massry S. G., Goldstein D. A. The search for uremic toxin(s) "X" "X" = PTH. Clin Nephrol. 1979 Apr;11(4):181–189. [PubMed] [Google Scholar]
  15. Moriniere P., Roussel A., Tahiri Y., de Fremont J. F., Maurel G., Jaudon M. C., Gueris J., Fournier A. Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism. Proc Eur Dial Transplant Assoc. 1983;19:784–787. [PubMed] [Google Scholar]
  16. Nathan E., Pedersen S. E. Dialysis encephalopathy in a non-dialysed uraemic boy treated with aluminium hydroxide orally. Acta Paediatr Scand. 1980 Nov;69(6):793–796. doi: 10.1111/j.1651-2227.1980.tb07155.x. [DOI] [PubMed] [Google Scholar]
  17. Norman M. E., Mazur A. T., Borden S., 4th, Gruskin A., Anast C., Baron R., Rasmussen H. Early diagnosis of juvenile renal osteodystrophy. J Pediatr. 1980 Aug;97(2):226–232. doi: 10.1016/s0022-3476(80)80479-3. [DOI] [PubMed] [Google Scholar]
  18. Poisson M., Mashaly R., Lebkiri B. Dialysis encephalopathy: recovery after interruption of aluminium intake. Br Med J. 1978 Dec 9;2(6152):1610–1611. doi: 10.1136/bmj.2.6152.1610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Portale A. A., Booth B. E., Halloran B. P., Morris R. C., Jr Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest. 1984 Jun;73(6):1580–1589. doi: 10.1172/JCI111365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rutherford W. E., Bordier P., Marie P., Hruska K., Harter H., Greenwalt A., Blondin J., Haddad J., Bricker N., Slatopolsky E. Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog. J Clin Invest. 1977 Aug;60(2):332–341. doi: 10.1172/JCI108781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sedman A. B., Miller N. L., Warady B. A., Lum G. M., Alfrey A. C. Aluminum loading in children with chronic renal failure. Kidney Int. 1984 Aug;26(2):201–204. doi: 10.1038/ki.1984.156. [DOI] [PubMed] [Google Scholar]
  22. Slatopolsky E., Caglar S., Gradowska L., Canterbury J., Reiss E., Bricker N. S. On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using "proportional reduction" of dietary phosphorus intake. Kidney Int. 1972 Sep;2(3):147–151. doi: 10.1038/ki.1972.84. [DOI] [PubMed] [Google Scholar]
  23. Slatopolsky E., Caglar S., Pennell J. P., Taggart D. D., Canterbury J. M., Reiss E., Bricker N. S. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest. 1971 Mar;50(3):492–499. doi: 10.1172/JCI106517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Slatopolsky E., Martin K., Hruska K. Parathyroid hormone metabolism and its potential as a uremic toxin. Am J Physiol. 1980 Jul;239(1):F1–12. doi: 10.1152/ajprenal.1980.239.1.F1. [DOI] [PubMed] [Google Scholar]
  25. Stickler G. B., Bergen B. J. A review: short stature in renal disease. Pediatr Res. 1973 Dec;7(12):978–982. doi: 10.1203/00006450-197312000-00006. [DOI] [PubMed] [Google Scholar]
  26. Tovey K. C., Oldham K. G., Whelan J. A. A simple direct assay for cyclic AMP in plasma and other biological samples using an improved competitive protein binding technique. Clin Chim Acta. 1974 Nov 8;56(3):221–234. doi: 10.1016/0009-8981(74)90133-8. [DOI] [PubMed] [Google Scholar]
  27. Walton R. J., Bijvoet O. L. Nomogram for derivation of renal threshold phosphate concentration. Lancet. 1975 Aug 16;2(7929):309–310. doi: 10.1016/s0140-6736(75)92736-1. [DOI] [PubMed] [Google Scholar]
  28. Woo J., Singer F. R. Radioimmunoassay for human parathyroid hormone. Clin Chim Acta. 1974 Jul 31;54(2):161–168. doi: 10.1016/0009-8981(74)90233-2. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES